Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression (2023)

First Author: González-Martínez I
Attributed to:  Preclinical Development of Peptide Oligonucleotides for Myotonic Dystrophy Type 1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.omtn.2023.09.001

Publication URI: http://dx.doi.org/10.1016/j.omtn.2023.09.001

Type: Journal Article/Review

Parent Publication: Molecular Therapy - Nucleic Acids